A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
5-fluorouracil (5-FU), one of the most actively investigated anti-cancer drugs, is rapidly
inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This
study will test the safety and effects of oral ADH300004 14 hours prior to oral 5-FU in
subjects with locally advanced, recurrent, or metastatic hepatocellular carcinoma.